Vanda Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $50,529 | $51,718 | $57,216 | $56,258 |
Gross Profit | 46,969 | 46,572 | 53,383 | 53,304 |
EBITDA | -63,247 | -44,897 | -32,139 | -26,337 |
EBIT | -65,234 | -48,424 | -38,002 | -28,390 |
Net Income | -62,513 | -48,567 | -141,187 | -22,586 |
Net Change In Cash | 50,529 | 51,718 | 57,216 | 56,258 |
Free Cash Flow | -81,699 | -50,439 | -29,519 | -31,787 |
Cash | 55,882 | 54,034 | 84,851 | 70,022 |
Basic Shares | 60,226 | 59,459 | 59,098 | 58,873 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $216,105 | $198,772 | $192,640 | $254,382 |
Gross Profit | 203,061 | 187,458 | 192,640 | 230,100 |
EBITDA | -126,730 | -14,789 | -13,952 | 14,033 |
EBIT | -138,647 | -22,921 | -13,952 | 11,300 |
Net Income | -220,474 | -18,900 | 2,509 | 6,275 |
Net Change In Cash | 216,105 | 198,772 | 192,640 | 254,382 |
Cost of Revenue | 82,643 | |||
Free Cash Flow | -110,440 | -16,247 | 12,418 | 31,305 |
Cash | 84,851 | 102,316 | 135,821 | 135,029 |
Basic Shares | 58,930 | 58,149 | 57,557 | 56,983 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.04 |
2026-03-31 | -$0.82 |
2025-12-31 | -$2.39 |
2025-09-30 | -$0.38 |